在我們實驗室過去的研究中，以經建構了一個結構完整且具擴展性的生物整合資料庫bio-database，我們將利用此生物資訊的方法，運用到腫瘤相關基因的研究。在過去的研究中發現，腫瘤細胞具有和人類胚胎細胞相似的表現型，因此我們相信存在某些胚胎表現的基因，雖然在正常成人的細胞中表現被關閉或是降低，但是在腫瘤細胞的形成中可以再被高度表現，使細胞回到未分化且具增生性的型態。我們從資料庫中初步找出69個基因，經由文獻搜尋的比對，30個在文獻中有較多的研究，而且有高達25個基因是跟腫瘤或是胚胎發育有關，只有五個基因跟我們預期的不符合；其中我們挑選了9個基因GDF11、EGRT-K2、IMP1、FGF18、FLJ10156、EGRT-U2、EGRT-U3、LOC129607、EGRT-U5以及另外一個已知跟腫瘤形成有關的cyclin D1在臨床的檢體中進行研究；檢體方面我們選用了19種不同的腫瘤，13種正常的組織以及從乳房、肺臟、胃、卵巢、腎臟、大腸等器官中挑選33種腫瘤/正常組織配對觀察，並且抽取六位正常成人的周邊血液利用RT-PCR來觀察這些基因表現，。其中GDF11、EGRT-U5、cyclin D1發現在腎臟細胞癌/正常腎臟組織間的表現是有差異性的；接著我們在腎臟癌細胞株ACHN中加入MEK抑制劑CI-1040，發現GDF11、cyclin D1表現有受到調控，更進一步的進行功能上的分析發現，在加入CI-1040的情況下，ACHN腎臟癌細胞株在活化態ERK被抑制的情況下，cyclin D1蛋白質表現也會被抑制住，大部分的細胞會進入G0/G1期，細胞的增生明顯的下降。結合此生物資訊的方法以及臨床檢體的分析，我們相信可以找出在腫瘤的形成中具有臨床潛力的基因。

　In previous studies，we have constructed an structured and scalable biological database – Bio-Database. We applied Bio-Database to the study of tumor-associated embryonic genes. It has been postulated that tumor cells exhibit similar phenotypes as embryonic cells. It is believed that there are embryonic genes which are silenced or down-regulated in normal adult cells, but reexpressed during tumor formation to “deprogram” the tumor cells. In order to find embryonic genes which may be important during tumorigenesis, we performed bioinformatic analyses using Bio-Database and obtained 69 candidate genes. We chose 9 candidate genes：GDF11, EGRT-K2, IMP1, FGF18, FLJ10156 ,EGRT-U2 ,EGRT-U3 ,LOC129607, EGRT-U5 and one known tumorigenci gene, cyclin D1, to test their expression in clinical samples by RT-PCR. The clinical samples include 19 different types of tumors, 33 samples of tumor/normal pairs from breast, lung, stomach, ovary, kidney, and colon, and samples of circulating blood cells from 6 healthy adults. We found that the expression of GDF11, EGRT-U5, cyclin D1 is different between renal cell carcinoma and normal renal tissues. After treating ACHN (a renal cell carcinoma cell line) with a MEK inhibitor, CI-1040, we found that the expression levels of GDF11 and cyclin D1 decreased. Western blot analysis confirmed that the cyclin D1 protein is inhibited in ACHN cells under CI1040 treatment. The ACHN cells were found to arrest in G0/G1 phase and reduce their ability to proliferate. Taken together, we believe that such a combined bioinformatic and experimental approach can identify genes with potential clinical applications.

Adams, M. D., Kelley, J. M., Gocayne, J. D., Dubnick, M., Polymeropoulos, M. H., Xiao, H., Merril, C. R., Wu, A., Olde, B., Moreno, R. F., and et al. (1991). Complementary DNA sequencing: expressed sequence tags and human genome project. Science 252, 1651-1656.
Antoine, M., Wirz, W., Tag, C. G., Mavituna, M., Emans, N., Korff, T., Stoldt, V., Gressner, A. M., and Kiefer, P. (2005). Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. Growth Factors 23, 87-95.
Ariel, I., Miao, H. Q., Ji, X. R., Schneider, T., Roll, D., de Groot, N., Hochberg, A., and Ayesh, S. (1998). Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol 51, 21-25.
DeLuca, J. G., Dong, Y., Hergert, P., Strauss, J., Hickey, J. M., Salmon, E. D., and McEwen, B. F. (2005). Hec1 and nuf2 are core components of the kinetochore outer plate essential for organizing microtubule attachment sites. Mol Biol Cell 16, 519-531.
Dutoit, V., Guillaume, P., Ayyoub, M., Hesdorffer, C. S., Luescher, I. F., and Valmori, D. (2003). Decreased binding of peptides-MHC class I (pMHC) multimeric complexes to CD8 affects their binding avidity for the TCR but does not significantly impact on pMHC/TCR dissociation rate. J Immunol 170, 5110-5117.
Ghaffari, M., Zeng, X., Whitsett, J. A., and Yan, C. (1997). Nuclear localization domain of thyroid transcription factor-1 in respiratory epithelial cells. Biochem J 328 ( Pt 3), 757-761.
Gilboa, E. (1999). The makings of a tumor rejection antigen. Immunity 11, 263-270.
Gure, A. O., Stockert, E., Scanlan, M. J., Keresztes, R. S., Jager, D., Altorki, N. K., Old, L. J., and Chen, Y. T. (2000). Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 97, 4198-4203.
Hanahan, D. (1983). Studies on transformation of Escherichia coli with plasmids. J Mol Biol 166, 557-580.
Hedberg, Y., Davoodi, E., Roos, G., Ljungberg, B., and Landberg, G. (1999). Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer 84, 268-272.
Heffelfinger, S. C., Yassin, R., Miller, M. A., and Lower, E. E. (2000). Cyclin D1, retinoblastoma, p53, and Her2/neu protein expression in preinvasive breast pathologies: correlation with vascularity. Pathobiology 68, 129-136.
Heim, M., Scharifi, M., Zisowsky, J., Jaehde, U., Voliotis, D., Seeber, S., and Strumberg, D. (2005). The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16, 129-136.
Hippo, Y., Watanabe, K., Watanabe, A., Midorikawa, Y., Yamamoto, S., Ihara, S., Tokita, S., Iwanari, H., Ito, Y., Nakano, K., et al. (2004). Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64, 2418-2423.
Holland, L. Z., Schubert, M., Holland, N. D., and Neuman, T. (2000). Evolutionary conservation of the presumptive neural plate markers AmphiSox1/2/3 and AmphiNeurogenin in the invertebrate chordate amphioxus. Dev Biol 226, 18-33.
Inaba, N., Okajima, Y., Ota, Y., Fukazawa, I., Yamaguchi, T., Sato, N., Sudo, H., Milanga, M., Takamizawa, H., Fujii, S., and et al. (1989). [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology]. Nippon Gan Chiryo Gakkai Shi 24, 2426-2435.
Ioannidis, P., Mahaira, L., Papadopoulou, A., Teixeira, M. R., Heim, S., Andersen, J. A., Evangelou, E., Dafni, U., Pandis, N., and Trangas, T. (2003). CRD-BP: a c-Myc mRNA stabilizing protein with an oncofetal pattern of expression. Anticancer Res 23, 2179-2183.
Ishikawa, T. O., Tamai, Y., Li, Q., Oshima, M., and Taketo, M. M. (2003). Requirement for tumor suppressor Apc in the morphogenesis of anterior and ventral mouse embryo. Dev Biol 253, 230-246.
Kithier, K., Samal, B., Cejka, J., Whitcomb, M. P., and Mood, D. W. (1988). Pancreatic oncofetal antigen and carcinoembryonic antigen in breast and colon carcinoma. Tumour Biol 9, 307-314.
Kolch, W. (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351 Pt 2, 289-305.
Leeds, P., Kren, B. T., Boylan, J. M., Betz, N. A., Steer, C. J., Gruppuso, P. A., and Ross, J. (1997). Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro. Oncogene 14, 1279-1286.
Lelle, R. J., Henkel, E., Leinemann, D., and Goeschen, K. (1989). Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest 27, 137-142.
Liao, B., Hu, Y., Herrick, D. J., and Brewer, G. (2005). The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280, 18517-18524.
Loganath, A., Peh, K. L., Gunasegaram, R., Thiagaraj, D., Cheah, E., Kottegoda, S. R., and Ratnam, S. S. (1988). Comparison of AFP and beta-hCG levels in infiltrating duct mammary carcinoma at different stages of malignancy. Pathology 20, 275-278.
Lorusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., Deluca, P., Bruzek, L., Piens, J., et al. (2005). Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies. J Clin Oncol.
Ma, L., Yin, H., Yang, W., Yang, G., Lu, Q., and Liu, X. (2001). [Differential expression of cyclins D1, E and A in human breast diseases]. Hua Xi Yi Ke Da Xue Xue Bao 32, 497-500.
Man, T. K., Lu, X. Y., Jaeweon, K., Perlaky, L., Harris, C. P., Shah, S., Ladanyi, M., Gorlick, R., Lau, C. C., and Rao, P. H. (2004). Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4, 45.
Manolopoulos, V. G., Liekens, S., Koolwijk, P., Voets, T., Peters, E., Droogmans, G., Lelkes, P. I., De Clercq, E., and Nilius, B. (2000). Inhibition of angiogenesis by blockers of volume-regulated anion channels. Gen Pharmacol 34, 107-116.
Matouk, I., Ayesh, B., Schneider, T., Ayesh, S., Ohana, P., de-Groot, N., Hochberg, A., and Galun, E. (2004). Oncofetal splice-pattern of the human H19 gene. Biochem Biophys Res Commun 318, 916-919.
Monk, M., and Holding, C. (2001). Human embryonic genes re-expressed in cancer cells. Oncogene 20, 8085-8091.
Nakatsura, T., Komori, H., Kubo, T., Yoshitake, Y., Senju, S., Katagiri, T., Furukawa, Y., Ogawa, M., Nakamura, Y., and Nishimura, Y. (2004). Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 10, 8630-8640.
Nakatsura, T., and Nishimura, Y. (2005). Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19, 71-77.
Nakatsura, T., Yoshitake, Y., Senju, S., Monji, M., Komori, H., Motomura, Y., Hosaka, S., Beppu, T., Ishiko, T., Kamohara, H., et al. (2003). Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306, 16-25.
Ochi, Y., Okabe, H., Inui, T., and Yamashiro, K. (1997). [Tumor marker--present and future]. Rinsho Byori 45, 875-883.
Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M., and Yoshida, O. (1995). Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55, 4182-4187.
Okamoto, Y., Yokoyama, S., Sasaki, A., Kashima, K., Daa, T., Nakayama, I., and Noguchi, S. (1996). Oncofetal expression of blood group-related antigen on morules in thyroid carcinoma. Pathol Int 46, 867-873.
Paintlia, M. K., Paintlia, A. S., Barbosa, E., Singh, I., and Singh, A. K. (2004). N-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J Neurosci Res 78, 347-361.
Pevny, L. H., Sockanathan, S., Placzek, M., and Lovell-Badge, R. (1998). A role for SOX1 in neural determination. Development 125, 1967-1978.
Pittock, S. J., Kryzer, T. J., and Lennon, V. A. (2004). Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 56, 715-719.
Rimoldi, D., Salvi, S., Reed, D., Coulie, P., Jongeneel, V. C., De Plaen, E., Brasseur, F., Rodriguez, A. M., Boon, T., and Cerottini, J. C. (1999). cDNA and protein characterization of human MAGE-10. Int J Cancer 82, 901-907.
Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22, 4456-4462.
Sebolt-Leopold, J. S. (2000). Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594-6599.
Severin, S. E., Posypanova, G. A., Katukov, V. U., Shmyrev, II, Luzhkov Yu, M., Gerasimova, G. K., Zhukova, O. S., Vorozhtsov, G. N., Kaliya, O. L., Lukyanets, E. A., and Severin, E. S. (1997). Antitumor activity of conjugates of the oncofetal protein alpha-fetoprotein and phthalocyanines in vitro. Biochem Mol Biol Int 43, 873-881.
Shimokawa, T., Furukawa, Y., Sakai, M., Li, M., Miwa, N., Lin, Y. M., and Nakamura, Y. (2003). Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res 63, 6116-6120.
Snider, L., Thirlwell, H., Miller, J. R., Moon, R. T., Groudine, M., and Tapscott, S. J. (2001). Inhibition of Tcf3 binding by I-mfa domain proteins. Mol Cell Biol 21, 1866-1873.
Sorensen, K. C., Kitchell, B. E., Schaeffer, D. J., and Mardis, P. E. (2004). Expression of matrix metalloproteinases in feline vaccine site-associated sarcomas. Am J Vet Res 65, 373-379.
Strauss, M., Lukas, J., and Bartek, J. (1995). Unrestricted cell cycling and cancer. Nat Med 1, 1245-1246.
Tran, P. T., Erdeniz, N., Symington, L. S., and Liskay, R. M. (2004). EXO1-A multi-tasking eukaryotic nuclease. DNA Repair (Amst) 3, 1549-1559.
Tzeng, C. C., Liu, H. S., Li, C., Jin, Y. T., Chen, R. M., Yang, W. H., and Lin, J. S. (1996). Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. Anticancer Res 16, 1797-1804.
van Spronsen, D. J., de Weijer, K. J., Mulders, P. F., and De Mulder, P. H. (2005). Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs 16, 709-717.
Wabnitz, P. A., Mitchell, D., and Wabnitz, D. A. (2004). In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human. Pharm Res 21, 1670-1679.
Wang, P., Wu, P., Egan, R. W., and Billah, M. M. (2003). Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene 314, 15-27.
Weinberg, R. A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
Yamauchi, N., Watanabe, A., Hishinuma, M., Ohashi, K. I., Midorikawa, Y., Morishita, Y., Niki, T., Shibahara, J., Mori, M., Makuuchi, M., et al. (2005). The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol.
Yen KH, L. C., Liu HS, Ho CL precise and scalable method for querying genes in chromosomal banding regions based on cytogenetic annotations.
Yenerel, M. N., Sundell, I. B., Weese, J., Bulger, M., and Gilligan, D. M. (2005). Expression of adducin genes during erythropoiesis: A novel erythroid promoter for ADD2. Exp Hematol 33, 758-766.
Yu, Z., Kryzer, T. J., Griesmann, G. E., Kim, K., Benarroch, E. E., and Lennon, V. A. (2001). CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49, 146-154.
Zhang, X., Wharton, W., Yuan, Z., Tsai, S. C., Olashaw, N., and Seto, E. (2004). Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol 24, 5106-5118.